Add 2 More Reports For 20% off

Report Overview

According to the National Psoriasis Foundation, approximately 30% of people who have psoriasis are also affected by psoriatic arthritis globally. This constitutes around 37.5 million people around the world. There are several various types of psoriatic arthritis, therefore finding effective solutions for the disease often requires multiple clinical trials. Several medications are in the pipeline and companies are developing effective and innovative treatments to manage the disease.

Key Takeaways

  • Major companies involved in the psoriatic arthritis pipeline drugs market include Janssen Research & Development, LLC, Novartis Pharmaceuticals and AbbVie among others.
  • Leading drugs currently under pipeline include Izokibep and Secukinumab among others.
  • Regulatory authorities such as the United States FDA and EMA play a critical role in psoriatic arthritis treatment as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients having psoriatic arthritis.

Report Coverage

The Psoriatic Arthritis Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing psoriatic arthritis clinical trials. It covers various aspects related to the details of psoriatic arthritis drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriatic arthritis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from psoriatic arthritis.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing psoriatic arthritis pipeline development activities are covered. Moreover, psoriatic arthritis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Psoriatic Arthritis Drug Pipeline Outlook

Psoriatic arthritis is a type of arthritis that is linked to psoriasis. Psoriasis is a chronic skin condition characterized by skin rashes, joint pain, stiffness, and changes in fingernails and toenails. Psoriatic arthritis has similar symptoms to rheumatoid arthritis , but it affects fewer joints than rheumatoid arthritis. There are several types of psoriatic arthritis and can be divided into five categories which include arthritis affecting small joints in the toes and fingers, asymmetrical arthritis of the joints in the hands, symmetrical polyarthritis, and arthritis mutilans (a rare type of arthritis that deforms joints) and psoriatic spondylitis which affects the lower back and spine.

The common symptoms of psoriatic arthritis include joint pain, stiffness, and redness near affected joints, swelling in fingers, pain where tendons and ligaments attach to the bones, silver or gray scaly patches on the scalp, knees, and elbows, knees, and discoloration or pitting on fingernails among others. The psoriatic arthritis treatment options include anti-inflammatory medicine like NSAIDs or acetaminophen, corticosteroids, cold or heat therapy, disease-modifying antirheumatic drugs (DMARDs) and physical therapy.

Several pharma companies and institutes are developing innovative treatments to manage psoriatic arthritis. There have been significant increases in the treatment options for psoriatic arthritis. Between 2013 and 2017, the FDA approved three new drugs to manage and treat psoriatic arthritis after clinical trials showed positive results. Researchers are exploring potential new therapies in clinical trials to manage the disease, thus impacting the psoriatic arthritis pipeline analysis.

Psoriatic Arthritis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of psoriatic arthritis  drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

EMR’s psoriatic arthritis  therapeutic assessment report covers 50+ drug analyses based on drug classes:

  • Recombinant Fusion Proteins
  • Small Molecule
  • Monoclonal Antibody
  • Peptide
  • Polymer
  • Gene Therapy

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

  • Oral
  • Parenteral
  • Others

Psoriatic Arthritis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for psoriatic arthritis with 108 pipeline drugs in phase III.

Psoriatic Arthritis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under psoriatic arthritis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapy. Gene therapy is a promising treatment for arthritis. It is an experimental technique to treat or prevent disease by introducing genetic material into cells to compensate for abnormal genes and replacing them with a healthy copy of the gene. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriatic arthritis.

Psoriatic Arthritis Clinical Trials Assessment – Competitive Dynamics

The EMR psoriatic arthritis drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Psoriatic Arthritis clinical trials:

  • ACELYRIN Inc.
  • Hansoh BioMedical R&D Company
  • Novartis Pharmaceuticals
  • MoonLake Immunotherapeutics AG
  • Aclaris Therapeutics, Inc.
  • Ventyx Biosciences, Inc
  • Enlivex Therapeutics Ltd.
  • AbbVie
  • Janssen Research & Development, LLC
  • Others

Psoriatic Arthritis – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for psoriatic arthritis. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriatic arthritis drug candidates.

Drug: Izokibep

The trial is designed to evaluate the safety and effectiveness of Izokibep which is a selective inhibitor of interleukin (IL)-17A for the treatment of psoriatic arthritis (PsA). The trial is sponsored by Hansoh BioMedical R&D Company and is currently under phase II.

Drug: HS-10374

The objective of the study is to explore the clinical safety and effectiveness of HS-10374 for the treatment of active psoriatic arthritis. The trial is sponsored by ACELYRIN Inc. and is currently under phase III.

Biological: Secukinumab

Novartis Pharmaceuticals is developing this psoriatic arthritis drug candidate and it is currently under phase III. The study is being conducted to compare the safety and effectiveness of secukinumab and ustekinumab in patients with active psoriatic arthritis.

Reasons To Buy This Report

The Psoriatic Arthritis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriatic arthritis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into psoriatic arthritis collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Psoriatic Arthritis – Pipeline Assessment Report

  • Which companies/institutions are leading the psoriatic arthritis drug development?
  • What is the efficacy and safety profile of psoriatic arthritis pipeline drugs?
  • Which company is leading the psoriatic arthritis pipeline development activities?
  • What is the current psoriatic arthritis commercial assessment?
  • What are the opportunities and challenges present in the psoriatic arthritis drug pipeline landscape?
  • What is the efficacy and safety profile of psoriatic arthritis pipeline drugs?
  • Which company is conducting major trials for psoriatic arthritis drugs?
  • Which companies/institutions are involved in psoriatic arthritis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in psoriatic arthritis?

Related Reports

Psoriatic Arthritis Treatment Market

Canine Arthritis Treatment Market

Rheumatoid Arthritis Therapeutics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
Route of Administration
  • Oral
  • Parenteral
  • Others
Drug Classes
  • Recombinant Fusion Proteins
  • Small Molecule
  • Monoclonal Antibody
  • Peptide
  • Polymer
  • Gene Therapy
Leading Sponsors Covered
  • ACELYRIN Inc.
  • Hansoh BioMedical R&D Company
  • Novartis Pharmaceuticals
  • MoonLake Immunotherapeutics AG
  • Aclaris Therapeutics, Inc.
  • Ventyx Biosciences, Inc
  • Enlivex Therapeutics Ltd.
  • AbbVie
  • Janssen Research & Development, LLC
  • Others
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

Purchase Full Report

Datasheet

 

USD 2,199

USD 1,899

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 2,749

USD 2,299

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 3,849

USD 3,299

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 4,949

USD 4,199

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124